Out-licensing
Up-to-date access to technology licensing opportunities worldwide.
- Out-licensing
- Browse
Licensing opportunities
Ultrashort acting beta blocker Esmolol for use in anesthesia, intensive care, cardiology and internal medicine. More
Supercritical fluid crystal and particle engineering to form particles with strong aerodynamic performance and exceptional size uniformity for optimised pulmonary/nasal delivery More
Ultrashort acting beta blocker Esmolol for use in anesthesia, intensive care, cardiology and internal medicine. More
Related Reports
Market Research Reports provided by reports.iptechex.com
Nov 2010 - 5 pages - $500
Nov 2010 - 329 pages - $1,495
Feb 2011 - 62 pages - $500
Jul 2011 - 46 pages - $3,800
May 2007 - 183 pages - $2,875
Sep 2011 - 106 pages - $500
Dec 2010 - 49 pages - $2,000
Mar 2010 - 180 pages - $3,835
Aug 2008 - 120 pages - $1,040
Your selection
Browse By
- Industry sector
- Assay systems
- Diagnostic test systems
- Gene therapy
- Human diagnostics
- Human therapeutics
- Nanotechnology
- Other
- Research supplies
- Stem cells
- Therapeutic target
- Angina
- Angina pectoris
- Angina, chronic stable
- Angina, unstable
- Arrhythmia
- Atrial fibrillation
- Cardiac arrythmia
- Cardiomyopathy
- Congestive heart failure
- Coronary artery disease
- Coronary heart disease
- Heart failure
- Ischaemic heart disease
- Myocardial infarction
© Copyright 1998-2013 IP Technology Exchange, Inc All rights reserved. Terms and Conditions | Contact us